Literature DB >> 23066315

Clinical outcome and predictors of survival after TIPS insertion in patients with liver cirrhosis.

Hauke S Heinzow1, Philipp Lenz, Michael Köhler, Frank Reinecke, Hansjörg Ullerich, Wolfram Domschke, Dirk Domagk, Tobias Meister.   

Abstract

AIM: To determine the clinical outcome and predictors of survival after transjugular intrahepatic portosystemic stent shunt (TIPS) implantation in cirrhotic patients.
METHODS: Eighty-one patients with liver cirrhosis and consequential portal hypertension had TIPS implantation (bare metal) for either refractory ascites (RA) (n = 27) or variceal bleeding (VB) (n = 54). Endpoints for the study were: technical success, stent occlusion and stent stenosis, rebleeding, RA and mortality. Clinical records of patients were collected and analysed. Baseline characteristics [e.g., age, sex, CHILD score and the model for end-stage liver disease score (MELD score), underlying disease] were retrieved. The Kaplan-Meier method was employed to calculate survival from the time of TIPS implantation and comparisons were made by log rank test. A multivariate analysis of factors influencing survival was carried out using the Cox proportional hazards regression model. Results were expressed as medians and ranges. Comparisons between groups were performed by using the Mann-Whitney U-test and the χ2 test as appropriate.
RESULTS: No difference could be seen in terms of age, sex, underlying disease or degree of portal pressure gradient (PPG) reduction between the ascites and the bleeding group. The PPG significantly decreased from 23.4 ± 5.3 mmHg (VB) vs. 22.1 ± 5.5 mmHg (RA) before TIPS to 11.8 ± 4.0 vs. 11.7 ± 4.2 after TIPS implantation (P = 0.001 within each group). There was a tendency towards more patients with stage CHILD A in the bleeding group compared to the ascites group (24 vs 6, P = 0.052). The median survival for the ascites group was 29 mo compared to > 60 mo for the bleeding group (P = 0.009). The number of radiological controls for stent patency was 6.3 for bleeders and 3.8 for ascites patients (P = 0.029). Kaplan-Meier calculation indicated that stent occlusion at first control (P = 0.027), ascites prior to TIPS implantation (P = 0.009), CHILD stage (P = 0.013), MELD score (P = 0.001) and those patients not having undergone liver transplantation (P = 0.024) were significant predictors of survival. In the Cox regression model, stent occlusion (P = 0.022), RA (P = 0.043), CHILD stage (P = 0.015) and MELD score (P = 0.004) turned out to be independent prognostic factors of survival. The anticoagulation management (P = 0.097), the porto-systemic pressure gradient (P = 0.460) and rebleeding episodes (P = 0.765) had no significant effect on the overall survival.
CONCLUSION: RA, stent occlusion, initial CHILD stage and MELD score are independent predictors of survival in patients with TIPS, speaking for a close follow-up in these circumstances.

Entities:  

Keywords:  Ascites; Gastrointestinal hemorrhage; Liver cirrhosis; Transjugular intrahepatic portosystemic stent shunt; Treatment outcome

Mesh:

Substances:

Year:  2012        PMID: 23066315      PMCID: PMC3468853          DOI: 10.3748/wjg.v18.i37.5211

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  51 in total

Review 1.  Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis.

Authors:  G Garcia-Tsao
Journal:  Gastroenterology       Date:  2001-02       Impact factor: 22.682

2.  MELD and PELD: application of survival models to liver allocation.

Authors:  R H Wiesner; S V McDiarmid; P S Kamath; E B Edwards; M Malinchoc; W K Kremers; R A Krom; W R Kim
Journal:  Liver Transpl       Date:  2001-07       Impact factor: 5.799

Review 3.  ASH and NASH.

Authors:  F Scaglioni; S Ciccia; M Marino; G Bedogni; S Bellentani
Journal:  Dig Dis       Date:  2011-07-05       Impact factor: 2.404

4.  A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts.

Authors:  M Malinchoc; P S Kamath; F D Gordon; C J Peine; J Rank; P C ter Borg
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

5.  Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis.

Authors:  Angelo Luca; Roberto Miraglia; Settimo Caruso; Mariapina Milazzo; Cristina Sapere; Luigi Maruzzelli; Giovanni Vizzini; Fabio Tuzzolino; Bruno Gridelli; Jaime Bosch
Journal:  Gut       Date:  2011-02-28       Impact factor: 23.059

6.  How much reduction in portal pressure is necessary to prevent variceal rebleeding? A longitudinal study in 225 patients with transjugular intrahepatic portosystemic shunts.

Authors:  M Rössle; V Siegerstetter; M Olschewski; A Ochs; E Berger; K Haag
Journal:  Am J Gastroenterol       Date:  2001-12       Impact factor: 10.864

7.  MELD score less than 15 predicts prolonged survival after transjugular intrahepatic portosystemic shunt for refractory ascites after liver transplantation.

Authors:  Eyob Feyssa; Jorge Ortiz; Kevin Grewal; Ashaur Azhar; Afshin Parsikia; Kashif Tufail; Nikroo Hashemi; Paul Brady; Victor Araya
Journal:  Transplantation       Date:  2011-04-15       Impact factor: 4.939

Review 8.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

9.  Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial.

Authors:  Yoshiyuki Narahara; Hidenori Kanazawa; Takeshi Fukuda; Yoko Matsushita; Hirotomo Harimoto; Hideko Kidokoro; Tamaki Katakura; Masanori Atsukawa; Yasuhiko Taki; Yuu Kimura; Katsuhisa Nakatsuka; Choitsu Sakamoto
Journal:  J Gastroenterol       Date:  2010-07-15       Impact factor: 7.527

10.  Model for end-stage liver disease (MELD) and allocation of donor livers.

Authors:  Russell Wiesner; Erick Edwards; Richard Freeman; Ann Harper; Ray Kim; Patrick Kamath; Walter Kremers; John Lake; Todd Howard; Robert M Merion; Robert A Wolfe; Ruud Krom
Journal:  Gastroenterology       Date:  2003-01       Impact factor: 22.682

View more
  11 in total

1.  Nationwide trends and predictors of inpatient mortality in 83884 transjugular intrahepatic portosystemic shunt.

Authors:  Edward Wolfgang Lee; Andrew Kuei; Sammy Saab; Ronald W Busuttil; Francisco Durazo; Steven-Huy Han; Mohamed M El-Kabany; Justin P McWilliams; Stephen T Kee
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

2.  Transjugular intrahepatic portosystemic shunt for the treatment of medically refractory ascites.

Authors:  Ahmad Parvinian; James T Bui; M Grace Knuttinen; Jeet Minocha; Ron C Gaba
Journal:  Diagn Interv Radiol       Date:  2014 Jan-Feb       Impact factor: 2.630

3.  Predicting death or recurrence of portal hypertension symptoms after TIPS procedures.

Authors:  Shawn H Sun; Thomas Eche; Chloé Dorczynski; Philippe Otal; Paul Revel-Mouroz; Charline Zadro; Ephraim Partouche; Nadim Fares; Charlotte Maulat; Christophe Bureau; Lawrence H Schwartz; Hervé Rousseau; Laurent Dercle; Fatima-Zohra Mokrane
Journal:  Eur Radiol       Date:  2022-01-11       Impact factor: 5.315

4.  Elective Transjugular Intrahepatic Portosystemic Shunt Using Viatorr Stent-Grafts: A Single-Center Experience from China.

Authors:  Yu-Hua Li; Yue-Meng Wan; Hua-Mei Wu; Song-Quan Huang
Journal:  J Belg Soc Radiol       Date:  2022-06-29       Impact factor: 1.912

5.  Transjugular intrahepatic portosystemic shunt with covered stents for hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Jian-Bo Zhao; Chao Feng; Qiao-Hua Zhu; Xiao-Feng He; Yan-Hao Li; Yong Chen
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

Review 6.  Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications.

Authors:  Sith Siramolpiwat
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

7.  Efficacy of covered and bare stent in TIPS for cirrhotic portal hypertension: A single-center randomized trial.

Authors:  Lei Wang; Zhibo Xiao; Zhendong Yue; Hongwei Zhao; Zhenhua Fan; Mengfei Zhao; Fuliang He; Shan Dai; Bin Qiu; Jiannan Yao; Qiushi Lin; Xiaoqun Dong; Fuquan Liu
Journal:  Sci Rep       Date:  2016-02-15       Impact factor: 4.379

8.  TIPS vs. endoscopic treatment for prevention of recurrent variceal bleeding: a long-term follow-up of 126 patients.

Authors:  Spela Korsic; Borut Stabuc; Pavel Skok; Peter Popovic
Journal:  Radiol Oncol       Date:  2021-01-26       Impact factor: 2.991

9.  Use of concomitant variceal embolization and prophylactic antiplatelet/anticoagulative in transjugular intrahepatic portosystemic shunting: A retrospective study of 182 cirrhotic portal hypertension patients.

Authors:  Yingmei Tang; Sheng Zheng; Jinhui Yang; Weimin Bao; Lihong Yang; Yingchun Li; Ying Xu; Jing Yang; Yuyun Tong; Jinhang Gao; Chengwei Tang
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

10.  Long-term clinical outcomes in patients with viral hepatitis related liver cirrhosis after transjugular intrahepatic portosystemic shunt treatment.

Authors:  Dengke Teng; Hao Zuo; Lin Liu; Jinghui Dong; Lei Ding
Journal:  Virol J       Date:  2018-10-01       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.